Regulatory Approval (M&A)
Regulatory approval in M&A refers to the process of obtaining clearance from government agencies — including antitrust regulators, sector-specific regulators, and national security bodies — that is required before a merger or acquisition can legally close.
Large mergers and acquisitions require approval from multiple regulatory bodies before they can be consummated. The specific approvals required depend on the size of the transaction, the industries involved, the nationalities of the parties, and the geographic markets affected. In the United States, the primary regulatory requirements are antitrust clearance under the HSR Act (from the FTC or DOJ) and, for cross-border deals, national security review by CFIUS. Additional approvals may be required from sector regulators.
In regulated industries, sector-specific regulatory bodies must approve changes of control before a transaction can close. Bank mergers require approval from the Federal Reserve, Office of the Comptroller of the Currency, FDIC, and often state banking regulators. Insurance company acquisitions must be approved by state insurance commissioners in each state where the target is licensed. Telecommunications transactions require FCC approval for licenses transferred in the deal. Utility acquisitions must be approved by FERC, state public utility commissions, and nuclear regulatory bodies if nuclear assets are involved. Each of these processes has its own timeline, procedural requirements, and substantive standards.
Foreign regulatory approvals add substantial complexity to cross-border transactions. A merger of two global companies may trigger mandatory notification and review obligations in the European Union, the United Kingdom, China, Japan, Canada, and dozens of other jurisdictions simultaneously. Each jurisdiction applies its own legal standards and has its own timeline — some requiring only a few weeks, others taking twelve to eighteen months. A deal that clears in the US and Europe may still be blocked or heavily conditioned by Chinese regulators, as occurred with several semiconductor transactions in the 2020s.
From a deal structure perspective, regulatory approval conditions are critical terms of the merger agreement. The agreement specifies which regulatory approvals are conditions to closing, what efforts each party is obligated to make to obtain them ('reasonable best efforts,' 'commercially reasonable efforts,' or 'hell or high water'), and what happens if approval is denied or conditioned on unacceptable remedies. A 'regulatory out' or 'walk right' allows a buyer to terminate the deal if required divestitures exceed a specified threshold.
Regulatory risk has grown meaningfully since the mid-2010s across most major jurisdictions, as antitrust authorities have taken increasingly aggressive positions on technology platforms, healthcare consolidation, and telecommunications mergers. Deal timelines have extended, and remedies have become more structural and onerous, reshaping how boards and advisors assess deal feasibility at the outset.